National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons

Neil Majithia, Sarah M. Temkin, Kathryn J Ruddy, Andreas S Beutler, Dawn L. Hershman, Charles Lawrence Loprinzi

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and debilitating complications of cancer treatment. Due to a lack of effective management options for patients with CIPN, the National Cancer Institute (NCI) sponsored a series of trials aimed at both prevention and treatment. A total of 15 such studies were approved, evaluating use of various neuro-modulatory agents which have shown benefit in other neuropathic pain states. Aside from duloxetine, none of the pharmacologic methods demonstrated therapeutic benefit for patients with CIPN. Despite these disappointing results, the series of trials revealed important lessons that have informed subsequent work. Some examples of this include the use of patient-reported symptom metrics, the elimination of traditional—yet unsubstantiated—practice approaches, and the discovery of molecular genetic predictors of neuropathy. Current inquiry is being guided by the results from these large-scale trials, and as such, stands better chance of identifying durable solutions for this treatment-limiting toxicity.

Original languageEnglish (US)
Pages (from-to)1439-1447
Number of pages9
JournalSupportive Care in Cancer
Volume24
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

National Cancer Institute (U.S.)
Peripheral Nervous System Diseases
Drug Therapy
Neuralgia
Therapeutics
Molecular Biology
Neoplasms

Keywords

  • Cancer
  • Chemotherapy
  • Clinical trials
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Oncology

Cite this

National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials : outcomes and lessons. / Majithia, Neil; Temkin, Sarah M.; Ruddy, Kathryn J; Beutler, Andreas S; Hershman, Dawn L.; Loprinzi, Charles Lawrence.

In: Supportive Care in Cancer, Vol. 24, No. 3, 01.03.2016, p. 1439-1447.

Research output: Contribution to journalArticle

@article{32a93570419c423c9d1ae0609c850945,
title = "National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons",
abstract = "Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and debilitating complications of cancer treatment. Due to a lack of effective management options for patients with CIPN, the National Cancer Institute (NCI) sponsored a series of trials aimed at both prevention and treatment. A total of 15 such studies were approved, evaluating use of various neuro-modulatory agents which have shown benefit in other neuropathic pain states. Aside from duloxetine, none of the pharmacologic methods demonstrated therapeutic benefit for patients with CIPN. Despite these disappointing results, the series of trials revealed important lessons that have informed subsequent work. Some examples of this include the use of patient-reported symptom metrics, the elimination of traditional—yet unsubstantiated—practice approaches, and the discovery of molecular genetic predictors of neuropathy. Current inquiry is being guided by the results from these large-scale trials, and as such, stands better chance of identifying durable solutions for this treatment-limiting toxicity.",
keywords = "Cancer, Chemotherapy, Clinical trials, Peripheral neuropathy",
author = "Neil Majithia and Temkin, {Sarah M.} and Ruddy, {Kathryn J} and Beutler, {Andreas S} and Hershman, {Dawn L.} and Loprinzi, {Charles Lawrence}",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00520-015-3063-4",
language = "English (US)",
volume = "24",
pages = "1439--1447",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials

T2 - outcomes and lessons

AU - Majithia, Neil

AU - Temkin, Sarah M.

AU - Ruddy, Kathryn J

AU - Beutler, Andreas S

AU - Hershman, Dawn L.

AU - Loprinzi, Charles Lawrence

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and debilitating complications of cancer treatment. Due to a lack of effective management options for patients with CIPN, the National Cancer Institute (NCI) sponsored a series of trials aimed at both prevention and treatment. A total of 15 such studies were approved, evaluating use of various neuro-modulatory agents which have shown benefit in other neuropathic pain states. Aside from duloxetine, none of the pharmacologic methods demonstrated therapeutic benefit for patients with CIPN. Despite these disappointing results, the series of trials revealed important lessons that have informed subsequent work. Some examples of this include the use of patient-reported symptom metrics, the elimination of traditional—yet unsubstantiated—practice approaches, and the discovery of molecular genetic predictors of neuropathy. Current inquiry is being guided by the results from these large-scale trials, and as such, stands better chance of identifying durable solutions for this treatment-limiting toxicity.

AB - Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and debilitating complications of cancer treatment. Due to a lack of effective management options for patients with CIPN, the National Cancer Institute (NCI) sponsored a series of trials aimed at both prevention and treatment. A total of 15 such studies were approved, evaluating use of various neuro-modulatory agents which have shown benefit in other neuropathic pain states. Aside from duloxetine, none of the pharmacologic methods demonstrated therapeutic benefit for patients with CIPN. Despite these disappointing results, the series of trials revealed important lessons that have informed subsequent work. Some examples of this include the use of patient-reported symptom metrics, the elimination of traditional—yet unsubstantiated—practice approaches, and the discovery of molecular genetic predictors of neuropathy. Current inquiry is being guided by the results from these large-scale trials, and as such, stands better chance of identifying durable solutions for this treatment-limiting toxicity.

KW - Cancer

KW - Chemotherapy

KW - Clinical trials

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=84955632359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955632359&partnerID=8YFLogxK

U2 - 10.1007/s00520-015-3063-4

DO - 10.1007/s00520-015-3063-4

M3 - Article

C2 - 26686859

AN - SCOPUS:84955632359

VL - 24

SP - 1439

EP - 1447

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 3

ER -